When it rains, it pours. I mean, what a crazy Monday for deals and data in biopharma.    Read More

Everyone’s talking about the July stock market rally. And, of course, you can’t overlook the outperformance of biotech—big and small.    Read More

The cost of drugs was a hot topic at ASCO this year, especially with the release of the big test results combining two very expensive treatments for lung cancer. The study showed using Avastin from Roche and Genentech and a pill, Tarceva, from OSI Pharmaceuticals, Roche and Genentech slowed down progression of the disease by a little more than a month.    Read More

The fight against cancer sparked a new partnership – and both the medical community and financial community are celebrating.   Read More

Consumers may be saving more and spending less, but big pharma is on a shopping spree. And I'm not talking about the really big deals including Roche buying Genentech, Pfizer buying Wyeth and Merck buying Schering-Plough. I'm talking about the two deals that have been done in less than a week between major drug companies and baby biotechs specializing in oncology.    Read More

Investors are closely watching the latest ASCO data released Thursday 6pm ET. Results seem likely to move the market.   Read More